WO2023021335 - PROTEIN ARRAY-BASED IN VITRO TRANSGLUTAMINASE ASSAY FOR EPITOPE MAPPING AND IMMUNOGEN DESIGN
National phase entry:
Publication Number
WO/2023/021335
Publication Date
23.02.2023
International Application No.
PCT/IB2022/000547
International Filing Date
19.08.2022
Title **
[English]
PROTEIN ARRAY-BASED IN VITRO TRANSGLUTAMINASE ASSAY FOR EPITOPE MAPPING AND IMMUNOGEN DESIGN
[French]
PLATE-FORME DE DOSAGE DE TRANSGLUTAMINASE IN VITRO BASÉE SUR UNE PUCE À PROTÉINES POUR CARTOGRAPHIE D'ÉPITOPES ET CONCEPTION D'IMMUNOGÈNE
Applicants **
LIU, Chen
Inventors
LIU, Chen
Priority Data
63/235,135
20.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter II
* |
| * | |
| * | |
| * | |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1971 | |
| EPO | Filing, Examination, Granting | 8697 | |
| Japan | Filing, Examination, Granting | 1908 | |
| South Korea | Filing, Examination, Granting | 1606 | |
| USA | Filing, Examination, Granting | 6110 |
Total:
20,292
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention provides methods for the determination and manipulation of immunodominant epitopes via respectively mapping and optimizing the glutamine-containing transglutaminase modification motifs. The invention discovers that the acyl donor glutamine-containing transglutaminase modification motifs of a peptide compose and correspond to the immunodominant epitope sequences recognized by the immunity, and the motifs' transglutaminase reactivity positively correlates with their immunogenicity. The invention further provides an approach for immunogen design wherein the immunogenicity of a protein could be manipulated through protein engineering measures changing the transglutaminase reactivity like amino acid substitution/mutation, deletion, or insertion, direct introduction/creation of glutamine residues/motifs, or any combination thereof.[French]
La présente invention concerne des méthodes pour la détermination et la manipulation d'épitopes immunodominants par l'intermédiaire respectivement d'une cartographie et d'une optimisation des motifs de modification de transglutaminase contenant de la glutamine. L'invention révèle que les motifs de modification de transglutaminase contenant de la glutamine donneurs d'acyle d'un peptide composent les séquences d'épitopes immunodominants reconnues par l'immunité et correspondent à celles-ci, et la réactivité de la transglutaminase des motifs est en corrélation positive avec leur immunogénicité. L'invention concerne en outre une approche pour la conception d'un immunogène, l'immunogénicité d'une protéine pouvant être manipulée par des mesures de génie protéique modifiant la réactivité de la transglutaminase comme la substitution/mutation, délétion, ou insertion d'acides aminés, l'introduction directe/la création de résidus/motifs de glutamine, ou toute combinaison de ceux-ci.